Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 115 record(s)

Req # A-2020-000664

Adverse Reaction Reports (AERs) for ONDANSETRON. Report numbers: 000910652, E2B_03062611, E2B_03095023, E2B_03151460.

Organization: Health Canada

82 page(s)
January 2021

Req # A-2020-000671

Adverse Reaction Report (AER) for Hydromorphone Hydrochloride. Report number: E2B_03142674.

Organization: Health Canada

160 page(s)
January 2021

Req # A-2020-000718

Adverse Reaction Report (AER) for FACTOR VII. Report number: E2B_03132694. ADR for ADDERALL XR: 000911513. ADRs for Amphetamine aspartate monohydrate: E2B_03072094, E2B_03099019. ADR for INTUNIV XR: 000915872. ADRs for MEZAVANT: E2B_03009989, E2B_03021516, E2B_03029508, E2B_03066067, E2B_03069502, E2B_03070574, E2B_03102099, E2B_03108058, E2B_03156394, E2B_03161189. ADRs for VYVANSE: 000738032 000908970, 000910227, 000911429, E2B_03150308.

Organization: Health Canada

211 page(s)
January 2021

Req # A-2020-000725

Adverse Reaction Reports (AERs). Report numbers: 000736518, E2B_02863275, E2B_03179765, E2B_02326291, E2B_02666714, E2B_03203966 E2B_03185578, E2B_03179136.

Organization: Health Canada

77 page(s)
January 2021

Req # A-2020-000762

Adverse Reaction Reports (AERs). Report numbers: E2B_03192015, E2B_03179854, E2B_01275749, E2B_03198903.

Organization: Health Canada

100 page(s)
January 2021

Req # A-2020-000812

Adverse Reaction Report (AER) for Botulinum toxin. Report number: E2B_02196696.

Organization: Health Canada

14 page(s)
January 2021

Req # A-2020-000820

Adverse Reaction Report (AER) for Botulinum toxin. Report number: E2B_03243531.

Organization: Health Canada

19 page(s)
January 2021

Req # A-2020-000831

Adverse Reaction Report (AER) for Botulinum toxin. Report number: E2B_03271551.

Organization: Health Canada

7 page(s)
January 2021

Req # A-2020-000832

Adverse Reaction Report (AER) for Botulinum toxin. Report number: E2B_03271550.

Organization: Health Canada

7 page(s)
January 2021

Req # A-2020-000835

Adverse Reaction Reports (AERs) for Pamidronate Disodium. Report numbers: E2B_02767440, E2B_02767451, E2B_02767852, E2B_02767858, E2B_02767922.

Organization: Health Canada

49 page(s)
January 2021
Date modified: